Stowe Z N, Bissette G, Nemeroff C B
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710.
Yakubutsu Seishin Kodo. 1991 Feb;11(1):49-59.
Despite the considerable data generated thus far, a unifying theory for the role(s) of NT in the CNS has not been achieved. However, several conclusions with clinical relevance can be made about neurotensin. First, NT is intimately associated with the mesolimbic DA system and has the ability to selectively modulate this system. Second, NT possesses a pharmacobehavioral profile that is similar to antipsychotic drugs, with many similarities to the atypical class of antipsychotics drugs. If the pathogenesis of schizophrenia is related to dopaminergic hyperactivity, then the existence of an endogenous NT system that modulates the activity of the DA system, may represent a mechanism for the prevention of psychosis. The ability of the atypical antipsychotic drugs to effectively reduce the symptoms of schizophrenia does not depend entirely upon the blockade of D2 receptors, yet many of these drugs alter NT concentrations. The development of NT receptor agonists that can cross the blood brain barrier may prove valuable in the treatment of schizophrenia, while avoiding the liability of EPS and TD.
尽管迄今为止已产生了大量数据，但尚未形成关于神经降压素（NT）在中枢神经系统中作用的统一理论。然而，关于神经降压素可以得出几个具有临床相关性的结论。首先，神经降压素与中脑边缘多巴胺（DA）系统密切相关，并且有能力选择性地调节该系统。其次，神经降压素具有与抗精神病药物相似的药理行为特征，与非典型抗精神病药物有许多相似之处。如果精神分裂症的发病机制与多巴胺能亢进有关，那么存在一个调节多巴胺系统活性的内源性神经降压素系统，可能代表了一种预防精神病的机制。非典型抗精神病药物有效减轻精神分裂症症状的能力并不完全取决于对D2受体的阻断，但其中许多药物会改变神经降压素的浓度。能够穿过血脑屏障的神经降压素受体激动剂的开发，可能在精神分裂症的治疗中被证明是有价值的，同时避免锥体外系反应（EPS）和迟发性运动障碍（TD）的风险。
